ClinicalTrials.gg
CompletedNCT02151461Updated Feb 27, 2018Results posted

Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients

A Phase 2 interventional study of Low Metformin and Metformin in Type 2 Diabetes Mellitus, sponsored by NuSirt Biopharma. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-27.

Sponsored by NuSirt Biopharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
154th of 287
96 · median 100
Started
2014
with 15 others
Phase 2
23 of 293
3 open now
Registered
193rd of 293
by date

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 154th largest by enrollment of the 287 interventional ones that give a count, is one of 16 that started in 2014, is one of 23 in phase 2, and was the 193rd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The goal of this study is to demonstrate that leucine in combination with a low does of metformin can serve as an adjunct to diet and exercise to improve blood glucose levels in type 2 diabetic subjects. This study will compare three doses of a leucine-metformin combination to the standard metformin dose in controlling blood glucose levels in type 2 diabetic patients.

Read the detailed description

This is a randomized, 4-week, active-controlled, double-blind study to evaluate the effect of various fixed-dose combinations of leucine and metformin compared to standard metformin monotherapy on glycemic control. In this study, standard metformin therapy will be defined as 1000 g/day for Day 1 to Day 14 and then escalated to 1700 g/day for Day 15 to Day 28. Subjects meeting all inclusion criteria and no exclusion criteria will be randomized to one of four treatment arms.

The primary objective of the study is to evaluate the change in fasting plasma glucose from Baseline (Day 1) to Week 4 (Day 28) in subjects receiving various fixed-dose combinations of leucine and metformin compared to standard metformin monotherapy. Secondary objectives will also assess changes in baseline-corrected plasma glucose and insulin area under the concentration curves from baseline to day 28 and changes in insulin secretory rates as assessed during a 3-hour meal tolerance test. Finally the effects of gastrointestinal symptoms will be assessed by subject questionnaires.

The study will include a total of 3 periods: screening or washout of current diabetic monotherapy, a pre-treatment period to ensure subjects will be compliant, and a treatment period of 4 weeks, with the first dosing of medication on day 1 of the study. Each day blood glucose readings will be measured and recorded by patients. Three-hour standardized meal tests will be performed at Baseline (Day 1) and at Study Termination (Day 28). In addition, two, 7-day continuous glucose assessments will be conducted, as well as two seven point glucose profiles. Patients will also be asked about any gastrointestinal side effects they experience.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Diabetes
  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over age 18 at study entry.
  • Male, or female, if female, meets all of the following criteria:
  • Not breastfeeding
  • or negative pregnancy test result (human chorionic gonadotropin, beta subunit [β- hCG]) at Screening (Visit 1) (not required for hysterectomized females)
  • If of and sexually active, must practice and be willing to continue to practice appropriate
  • Is diagnosed with type 2 diabetes mellitus and either not adequately controlled by: diet and exercise alone or diet and exercise plus a single, treatment for type 2 diabetes.
  • If treated with an oral anti-diabetes agent, be willing and able to withdraw from therapy for 4 weeks after the screening visit and prior to initiating study mediation at Baseline (Day 1/Visit 4).
  • Be willing to avoid acetaminophen use for intervals up to 10 days as required for study procedures (see Section 4.6)
  • Has a fasting plasma glucose ≥126 mg/dL to ≤220 mg/dL at Screening
  • Has an ≥7% to ≤8.5% at Screening
  • Has a ≤40 kg/m2
  • Clinical laboratory tests (hematology, clinical chemistry, and urinalysis) either normal or abnormal but consistent with type 2 diabetes mellitus.
  • Is able to read, understand, and sign the forms (ICF) and if applicable, an authorization to use and disclose protected health information form (consistent with health insurance portability and accountability act of 1996 [HIPAA] legislation), communicate with the investigator, and understand and comply with protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • renal dysfunction
  • If using any of the following medications, has not been on a stable treatment regimen for a minimum of 4 weeks prior to screening:

Lipid-lowering agents Anti-hypertensive medications Thyroid replacement therapy Non-steroidal anti-inflammatory agents

  • Unable to perform self-blood glucose monitoring employing a glucose meter.
  • History of active cardio- or cerebro-vascular disease with an event within the previous 6 months
  • Gastrointestinal disorders
  • Endocrine disorders other than type 2 diabetes
  • Chronic infection
  • Hepatic disease
  • Neurological or psychiatric diseases
  • History of other psychiatric disorders
  • Has been treated (within the last month), is currently treated, or is expected to require or undergo treatment with; any anti-diabetes medications (other than as allowed by the inclusion criteria), oral or parenteral .
  • Participation in a weight loss program within the past 3 months.
  • Weight change by more than 10 pounds during the past month.
  • History of alcohol or substance abuse in the past 3 months or a positive screen for alcohol or drugs of abuse at screening.
  • Has received any drug within 3 months of Screening.
  • Has donated blood within 3 months before Screening or is planning to donate blood during the study.
  • Has known allergies or to metformin or leucine
  • Is employed, contracted or has an immediate family member directly affiliated with NuSirt Biopharma.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Low Metformin

    3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin

    Drug: Low Metformin

  • Experimental
    Mid Metformin

    3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin

    Drug: Mid Metformin

  • Experimental
    High Metformin

    3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin

    Drug: High Metformin

  • Experimental
    Metformin Monotherapy

    3 Capsules BID each containing 166.7 mg of metformin with dose escalation to 283.3 mg capsules BID (1,700 mg/Day) at Day 14.

    Drug: Metformin

Interventions

  • 1100 mg L Leucine in combination with 125 mg of Metformin BID

    Also known as: Metformin, Leucine, L-Leucine

  • 500 mg metformin BID until day 14 with dose escalation at day 14 to 850 mg metformin BID

  • 1100 mg of Leucine in combination with 250 mg Metformin BID

    Also known as: Metformin, Leucine, L-Leucine

  • 1100 mg of Leucine in combination with 500 mg Metformin BID

    Also known as: Metformin, Leucine, L-Leucine

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 28 in Absolute Plasma Glucose Area Under the Curve (AUC) 0-3hr

    The primary endpoint for NS 0100 01 was the absolute plasma glucose AUC (0-3 hr) change from Day 1 to Day 28.

    Time frame: 0, 15min, 30min, 45min, 1hr, 1.5hrs, 2hrs, 2.5hrs and 3 hrs

Secondary outcomes

  1. Change From Baseline to Day 28 in Incremental Plasma Glucose Area Under the Curve (AUC)

    The baseline incremental (baseline-subtracted) glucose AUC0-3h was evaluated for treatment differences at baseline.

    Time frame: Baseline, Day 28

  2. Change in Fasting Plasma Glucose

    Change in fasting plasma glucose for the fixed dose leucine and metformin combination treatments A, B and C was evaluated.

    Time frame: Baseline, Day 28

  3. Change in Hemoglobin A1c (HbA1c)

    Changes in HbA1c which is a marker of long-term glucose control was assessed.

    Time frame: Baseline, Day 28

  4. Change in Homeostasis Model Assessment-estimated Insulin Resistance (HOMA-IR)

    Effect on insulin sensitivity across fixed-dose leucine and metformin combination treatments or the standard metformin reference treatment.

    Time frame: Baseline, Day 28

  5. Change In 7-Point Glucose Profiles

    The meal induced glucose change in pre-meal and post-meal glucose were measured 7 times during the day. Subjects self-monitored blood glucose (preprandial and postprandial) concentrations at least 7 times, including before and 1 to 2 hours after breakfast, lunch, dinner, and snacks). For each study day, the pre-meal values from the 7 point test for each subject were averaged to generate a single pre-meal glucose value. Similarly, for each study day the post-meal values from the 7-point test for each subject were averaged to generate a single post-meal glucose value. The average change from baseline (i.e., \[(Mean Pre/Post-meal value at Day 28 - Mean Pre/Post-meal value at Baseline) + (Mean Pre/Post-meal value at Day 21- Mean Pre/Post-meal value at Baseline) + (Mean Pre/Post-meal value at Day 7- Mean Pre/Post-meal value at Baseline)\]/ 3) over multiple time points listed in Time Frame. The mean pre-meal and post-meal values for baseline, day7, day 21 and day28 were used for comparison.

    Time frame: Baseline, Day 7, Day 21, Day 28

  6. Plasma Insulin Absolute and Incremental Meal Tolerance Test Area Under the Curve (AUC) 0-2hr

    Change in meal tolerance test insulin area under the curve (0-2 hr) from Day 1 to Day 28 for fixed-dose leucine and metformin combination treatments.

    Time frame: Baseline,Day 28

  7. Change From Baseline to Day 28 in Fasting Plasma Insulin Concentration

    Effect on fasting plasma insulin concentrations across fixed-dose leucine and metformin combination treatments or the standard metformin reference treatment was evaluated.

    Time frame: Baseline, Day 28

07

Results

Posted Feb 5, 2018

Participant flow

Subjects meeting all inclusion criteria and no exclusion criteria were randomized to one of four treatment arms in the ratio of 1:1:1:1 (A:B:C:D). The randomization was stratified by fasting plasma glucose (≥126 mg/dL to \<200 mg/dL, and ≥200 mg/dL to ≤220 mg/dL), as well as metformin experience. Yes/No history of abdominal side effects.

Participant flow — Overall Study
MilestoneFDC125FDC250FDC500Control
Started24252423
Completed18242119
Not completed6134
Withdrew: Adverse event5102
Withdrew: Lost to follow-up0011
Withdrew: Withdrawal by subject1011
Withdrew: Treatment discontinuation0010

Outcome measures

PrimaryChange From Baseline to Day 28 in Absolute Plasma Glucose Area Under the Curve (AUC) 0-3hr

The primary endpoint for NS 0100 01 was the absolute plasma glucose AUC (0-3 hr) change from Day 1 to Day 28.

Time frame:
0, 15min, 30min, 45min, 1hr, 1.5hrs, 2hrs, 2.5hrs and 3 hrs
Reported as:
Mean · mg*hrs/dL
Change From Baseline to Day 28 in Absolute Plasma Glucose Area Under the Curve (AUC) 0-3hr
mg*hrs/dLFDC125FDC250FDC500Control
Change From Baseline to Day 28 in Absolute Plasma Glucose Area Under the Curve (AUC) 0-3hr-18.005 ± 142.8374-45.029 ± 114.6701-64.010 ± 146.0917-141.848 ± 194.9300
Statistical analysis
  • FDC125 vs Control · ANCOVA · p = 0.0435 (Baseline plasma glucose AUC(0-3hr) is adjusted as a covariate.)
  • FDC250 vs Control · ANCOVA · p = 0.065
  • FDC500 vs Control · ANCOVA · p = 0.1216
SecondaryChange From Baseline to Day 28 in Incremental Plasma Glucose Area Under the Curve (AUC)

The baseline incremental (baseline-subtracted) glucose AUC0-3h was evaluated for treatment differences at baseline.

Time frame:
Baseline, Day 28
Reported as:
Mean · mg*hrs/dL
Change From Baseline to Day 28 in Incremental Plasma Glucose Area Under the Curve (AUC)
mg*hrs/dLFDC125FDC250FDC500Control
Change From Baseline to Day 28 in Incremental Plasma Glucose Area Under the Curve (AUC)-2.338 ± 60.2834-17.614 ± 93.1243-23.061 ± 64.6290-29.604 ± 86.1126
Statistical analysis
  • FDC125 vs Control · ANCOVA · p = 0.8867The model includes factors for treatment group and fasting plasma glucose stratum.
  • FDC250 vs Control · ANCOVA · p = 0.7641
  • FDC500 vs Control · ANCOVA · p = 0.2518
SecondaryChange in Fasting Plasma Glucose

Change in fasting plasma glucose for the fixed dose leucine and metformin combination treatments A, B and C was evaluated.

Time frame:
Baseline, Day 28
Reported as:
Mean · mg/dL
Change in Fasting Plasma Glucose
mg/dLFDC125FDC250FDC500Control
Change in Fasting Plasma Glucose-6.8 ± 36.91-9.7 ± 26.50-13.4 ± 38.55-36.0 ± 47.36
Statistical analysis
  • FDC125 vs Control · ANCOVA · p = 0.0179Total daily dose is twice the respective dose, Pairwise comparison using Treatment D as the reference group
  • FDC250 vs Control · ANCOVA · p = 0.0736
  • FDC500 vs Control · ANCOVA · p = 0.0475
SecondaryChange in Hemoglobin A1c (HbA1c)

Changes in HbA1c which is a marker of long-term glucose control was assessed.

Time frame:
Baseline, Day 28
Reported as:
Mean · percent
Change in Hemoglobin A1c (HbA1c)
percentFDC125FDC250FDC500Control
Change in Hemoglobin A1c (HbA1c)0.11 ± 0.448-0.16 ± 0.485-0.01 ± 0.442-0.23 ± 0.607
Statistical analysis
  • FDC125 vs Control · ANCOVA · p = 0.0089Total daily dose is twice the respective dose. Pairwise Comparison using Treatment D as the Reference Group
  • FDC250 vs Control · ANCOVA · p = 0.376
  • FDC500 vs Control · ANCOVA · p = 0.0578
SecondaryChange in Homeostasis Model Assessment-estimated Insulin Resistance (HOMA-IR)

Effect on insulin sensitivity across fixed-dose leucine and metformin combination treatments or the standard metformin reference treatment.

Time frame:
Baseline, Day 28
Reported as:
Mean · HOMA units
Change in Homeostasis Model Assessment-estimated Insulin Resistance (HOMA-IR)
HOMA unitsFDC125FDC250FDC500Control
Change in Homeostasis Model Assessment-estimated Insulin Resistance (HOMA-IR)-0.31 ± 1.010-0.14 ± 0.5480.11 ± 0.958-0.18 ± 1.017
Statistical analysis
  • FDC125 vs Control · ANCOVA · p = 0.2177Total daily dose is twice the respective dose. Pairwise Comparison using Treatment D as the Reference Group
  • FDC250 vs Control · ANCOVA · p = 0.4144
  • FDC500 vs Control · ANCOVA · p = 0.3117
SecondaryChange In 7-Point Glucose Profiles

The meal induced glucose change in pre-meal and post-meal glucose were measured 7 times during the day. Subjects self-monitored blood glucose (preprandial and postprandial) concentrations at least 7 times, including before and 1 to 2 hours after breakfast, lunch, dinner, and snacks). For each study day, the pre-meal values from the 7 point test for each subject were averaged to generate a single pre-meal glucose value. Similarly, for each study day the post-meal values from the 7-point test for each subject were averaged to generate a single post-meal glucose value. The average change from baseline (i.e., \[(Mean Pre/Post-meal value at Day 28 - Mean Pre/Post-meal value at Baseline) + (Mean Pre/Post-meal value at Day 21- Mean Pre/Post-meal value at Baseline) + (Mean Pre/Post-meal value at Day 7- Mean Pre/Post-meal value at Baseline)\]/ 3) over multiple time points listed in Time Frame. The mean pre-meal and post-meal values for baseline, day7, day 21 and day28 were used for comparison.

Time frame:
Baseline, Day 7, Day 21, Day 28
Reported as:
Mean · mg/dL
Change In 7-Point Glucose Profiles
mg/dLFDC125FDC250FDC500Control
28 day change in Pre-meal Glucose Level-6.50 ± 32.343-8.96 ± 61.561-25.51 ± 42.198-53.78 ± 45.488
28 day change in Post-meal Glucose Level-15.98 ± 33.96610.56 ± 44.944-34.25 ± 77.268-50.33 ± 60.756
Statistical analysis
  • FDC125 vs Control · ANCOVA · p = 0.011Total daily dose is twice the respective dose Pairwise comparison using Treatment D as the reference group
  • FDC250 vs Control · ANCOVA · p = 0.0152
  • FDC500 vs Control · ANCOVA · p = 0.0284
  • FDC125 vs Control · ANCOVA · p = 0.1273Total daily dose is twice the respective dose Pairwise comparison using Treatment D as the reference group
  • FDC250 vs Control · ANCOVA · p = 0.0085
  • FDC500 vs Control · ANCOVA · p = 0.1289
SecondaryPlasma Insulin Absolute and Incremental Meal Tolerance Test Area Under the Curve (AUC) 0-2hr

Change in meal tolerance test insulin area under the curve (0-2 hr) from Day 1 to Day 28 for fixed-dose leucine and metformin combination treatments.

Time frame:
Baseline,Day 28
Reported as:
Mean · h*ulU/ml
Plasma Insulin Absolute and Incremental Meal Tolerance Test Area Under the Curve (AUC) 0-2hr
h*ulU/mlFDC125FDC250FDC500Control
Plasma Insulin Absolute-0.19 ± 74.531-5.64 ± 31.360-9.59 ± 34.987-18.06 ± 35.473
Plasma Insulin Incremental4.18 ± 67.120-4.25 ± 29.514-9.99 ± 27.956-15.91 ± 26.720
Statistical analysis
  • FDC125 vs Control · ANCOVA · p = 0.3143Total daily dose is twice the respective dose. Pairwise comparison using Treatment D as the reference group.
  • FDC250 vs Control · ANCOVA · p = 0.5677
  • FDC500 vs Control · ANCOVA · p = 0.8407
SecondaryChange From Baseline to Day 28 in Fasting Plasma Insulin Concentration

Effect on fasting plasma insulin concentrations across fixed-dose leucine and metformin combination treatments or the standard metformin reference treatment was evaluated.

Time frame:
Baseline, Day 28
Reported as:
Mean · h*uIU/mL
Change From Baseline to Day 28 in Fasting Plasma Insulin Concentration
h*uIU/mLFDC125FDC250FDC500Control
Change From Baseline to Day 28 in Fasting Plasma Insulin Concentration-2.06 ± 6.652-0.74 ± 4.0690.20 ± 7.278-1.03 ± 7.694
Statistical analysis
  • FDC125 vs Control · ANCOVA · p = 0.9789Total daily dose is twice the respective dose Pairwise comparison using Treatment D as the reference group
  • FDC250 vs Control · ANCOVA · p = 0.841
  • FDC500 vs Control · ANCOVA · p = 0.748

Adverse events

Collected over 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FDC1250/24 (0%)1/24 (4.2%)3/24 (12.5%)
FDC2500/25 (0%)1/25 (4%)3/25 (12%)
FDC5000/24 (0%)0/24 (0%)3/24 (12.5%)
Control0/23 (0%)1/23 (4.3%)5/23 (21.7%)
Most frequent serious events
Most frequent serious events
EventFDC125FDC250FDC500Control
RhabdomyolysisMusculoskeletal and connective tissue disorders0/240/250/241/23
Suicidal IdeationPsychiatric disorders1/240/250/240/23
Lacunar InfarctionInfections and infestations0/241/250/240/23
Most frequent other events
Most frequent other events
EventFDC125FDC250FDC500Control
Gastric DisordersGastrointestinal disorders3/243/252/245/23
InfectionsInfections and infestations2/241/253/242/23
DisordersMusculoskeletal and connective tissue disorders0/241/253/242/23
Abdominal DistensionGeneral disorders0/240/250/242/23
FoodMetabolism and nutrition disorders2/240/250/240/23
Respiratory DisordersRespiratory, thoracic and mediastinal disorders2/241/250/240/23
ArthralgiaMusculoskeletal and connective tissue disorders0/240/252/240/23
HyperglycemiaEndocrine disorders2/240/250/240/23
Nervous DisordersNervous system disorders0/242/250/240/23

Baseline characteristics

Subjects who had adequate exposure to the randomized study medication during the 4-week treatment period (Day 1/Visit 4 to Day 28/Visit 7) and had adequately complied with the protocol as assessed by the sponsor prior to database lock.The groups in Metformin experience are mutually exclusive.

Age, Continuous
Age, Continuous(years)FDC125FDC250FDC500ControlTotal
Mean53.6 ± 9.8755.1 ± 8.356.1 ± 10.0859.3 ± 9.6456.0 ± 9.56
Age, Customized
Age, Customized(Participants)FDC125FDC250FDC500ControlTotal
<65 years1921181775
≥65 years546621
Sex: Female, Male
Sex: Female, Male(Participants)FDC125FDC250FDC500ControlTotal
Female1513131051
Male912111345
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FDC125FDC250FDC500ControlTotal
Hispanic or Latino1415121253
Not Hispanic or Latino1010121143
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FDC125FDC250FDC500ControlTotal
American Indian or Alaska Native01001
Asian01012
Native Hawaiian or Other Pacific Islander00000
Black or African American235616
White2220191677
More than one race00000
Unknown or Not Reported00000
Weight
Weight(kg)FDC125FDC250FDC500ControlTotal
Mean87.049 ± 17.374788.584 ± 19.468784.493 ± 19.862286.777 ± 16.570086.745 ± 18.1696
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)FDC125FDC250FDC500ControlTotal
Mean31.142 ± 4.711330.985 ± 5.576629.927 ± 5.150431.146 ± 4.583830.798 ± 4.9778
Fasting Plasma Glucose
Fasting Plasma Glucose(mg/dL)FDC125FDC250FDC500ControlTotal
Mean194.3 ± 50.86170.3 ± 44.28182.8 ± 40.97184.7 ± 50.87182.9 ± 46.93

2 further baseline measures are reported on the registry.

08

Study locations

9 sites
  • Catalina Research Institute
    Chino, California 91710, United States
  • Palm Beach Research
    Palm Beach, Florida 33409, United States
  • Meridien Research
    Tampa, Florida 33606, United States
  • River Birch Research Alliance
    Blue Ridge, Georgia 30513, United States
  • Meridian Research
    Savannah, Georgia 31406, United States
  • Streling Research Group
    Cincinnati, Ohio 45219, United States
  • Medical Research South
    Charleston, South Carolina 29407, United States
  • Meharry Medical College
    Nashville, Tennessee 37208, United States
  • Vanderbilt University Medical Center, Diabetes, Endocrinology, and Metabolism
    Nashville, Tennessee 37232, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Aug 2015 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2018, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2014
First posted
May 30, 2014
Start
Jul 2014
Primary completionActual
Aug 2015
CompletionActual
Jan 2016
Results first posted
Feb 5, 2018
Last update
Feb 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02151461
Lead sponsor
NuSirt Biopharma
Responsible party
Sponsor
First posted
May 30, 2014
Start date
Jul 2014
Primary completion
Aug 2015
Completion
Jan 2016
Results posted
Feb 5, 2018
Last update
Feb 27, 2018

Study contacts

Orville G Kolterman, MD
study chair · NuSirt Biopharma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion